Low Endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin

Chemotherapy

Volumn 56, Issue 5, 2010, Pages 364-370

  Trautmann, Matthias ^a,b   Scheibe, Cordula ^b   Wellinghausen, Nele ^b   Holst, Otto ^c   Lepper, Philipp M ^d  

^a KLINIKUM STUTTGART   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Ceftazidime; Endotoxin; Imipenem; Interleukin 1 ; Moxifloxacin; Sepsis; Septic shock; Tumor necrosis factor

Indexed keywords

CARBAPENEM; CEFTAZIDIME; ENDOTOXIN; IMIPENEM; INTERLEUKIN 1BETA; MOXIFLOXACIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTEROIDES FRAGILIS; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IN VITRO STUDY; LIMULUS LYSATE TEST; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEROIDES FRAGILIS; CEFTAZIDIME; ENDOTOXINS; ESCHERICHIA COLI; IMIPENEM; KINETICS; QUINOLINES;

EID: 77957315040     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321622     Document Type: Article

References (28)

1. Lepper PM, Held TK, Schneider EM, et al: Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 2002; 28: 824-833.
2. Holzheimer RG: Antibiotic-induced endotoxin release and clinical sepsis: A review. J Chemother 2001; 13: 159-172.
3. Jackson JJ, Kropp H: Beta-lactam antibioticinduced release of free endotoxin: In vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165: 1033-1041.
4. Bucklin SE, Fujihara Y, Leeson MC, Morrison DC : Differential antibiotic-induced release of endotoxin from gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13(suppl 1):S43-S51. (Pubitemid 24287900)
5. Dofferhoff AS, Nijland JH, de Vries-Hospers HG, et al: Effect of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: An in-vitro and in-vivo study. Scand J Infect Dis 1991; 23: 745-754.
6. Trautmann M, Heinemann M, Zick R, et al: Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic- induced morphological changes and endotoxin- liberating effects. Eur J Clin Microbiol Infect Dis 1998; 17: 754-760. (Pubitemid 29219126)
7. Trautmann M, Zick R, Rukavina T, et al: Antibiotic- induced release of endotoxin: In-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother 1998; 41: 163-169. (Pubitemid 28083118)
8. Trautmann M, Heinemann M, Möricke A, et al: Endotoxin release due to ciprofloxacin measured by three different methods. J Chemother 1999; 11: 248-254. (Pubitemid 29382618)
9. Periti P, Mazzei T: New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Int J Antimicrob Agents 1999; 12: 97-105. (Pubitemid 29276911)
10. Kaufman BM, Cross AS, Futrovsky SL, et al: Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are opsonic and protect mice against lethal challenge. Infect Immun 1986; 52: 617-619.
11. CLSI. Committee of Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility tests; approved standard, ed 10. 2009. www.clsi.org.
12. Wollenweber HW, Rietschel ET: Analysis of lipopolysaccharide (lipid A) fatty acids. J Microbiol Methods 1990; 11: 195-211. (Pubitemid 20207784)
13. Jones ME, Staples AM, Critchley I, et al: Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multicentre study. Diagn Microbiol Infect Dis 2000; 37: 203-211. (Pubitemid 30440732)
14. Bauernfeind A: Comparison of the antibacterial activities of the quinolones Bay 12- 8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-651. (Pubitemid 27503994)
15. Aldridge K, Ashcraft DS: Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-711. (Pubitemid 27098431)
16. Goldstein EJ: Intra-abdominal anaerobic infections: Bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002; 35(suppl 1):S106-S111.
17. Malangoni MA, Song J, Herrington J, et al: Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intraabdominal infections. Ann Surg 2006; 244: 204-211. (Pubitemid 44305534)
18. Ikawa K, Morikawa N, Sakamoto K, Ikeda K, Ohge H, Takesue Y, Sueda T: Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Chemotherapy 2008; 54: 131-139. (Pubitemid 351448600)
19. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596. (Pubitemid 43810035)
20. Prins JM, van Agtmael MA, Kuijper EJ, et al: Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: A double-blind study comparing imipenem and ceftazidime. J Infect Dis 1995; 172: 886-891.
21. Simpson AJ, Opal SM, Angus BJ, et al: Differential antibiotic-induced endotoxin release in severe melioidosis. J Infect Dis 2000; 181: 1014-1019.
22. Wolfert MA, Murray TF, Boons GJ, et al: The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem 2002; 277: 39179-39186.
23. Wexler HM: Bacteroides: The good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007; 20: 593-621.
24. Onderdonk AB, Bartlett JG, Louie T, et al: Microbial synergy in experimental intra-abdominal abscess. Infect Immun 1976; 13: 22-26.
25. Delahooke DM, Barcley GR, Poxton IR: A reappraisal of the biological activity of Bacteroides LPS. J Med Microbiol 1995; 42: 102-112.
26. Mancuso G, Midiri A, Biondo C, et al: Bacteroides fragilis -derived lipopolysaccharide produces cell activation and lethal toxicity via Toll-like receptor 4. Infect Immun 2005; 73: 5620-5627. (Pubitemid 41192997)
27. Rotimi VO, Verghese TL, Al-Sweih N, et al: Influence of five antianaerobic antibiotics on endotoxin liberation from gram-negative anaerobes. J Chemother 2000; 12: 40-47. (Pubitemid 30139827)
28. Rotstein OD, Vittorini T, Kao J, et al: A soluble Bacteroides by-product impairs phagocytic killing of Escherichia coli by neutrophils. Infect Immun 1989; 57: 745-753. (Pubitemid 19064534)